financetom
Business
financetom
/
Business
/
Ares Commercial beats Q3 profit expectations, declares dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ares Commercial beats Q3 profit expectations, declares dividend
Nov 7, 2025 3:25 AM

Overview

* Ares Commercial Q3 net income of $4.7 mln beats analyst expectations

* Company declared Q4 dividend of $0.15 per share

* Closed $271 mln of new loan commitments after Q3

Outlook

* Company anticipates additional repayments will enhance liquidity and support increased investment activity

* Ares Commercial Real Estate ( ACRE ) aims to accelerate investing activity with new loan commitments

Result Drivers

* LOAN REPAYMENTS - CFO Jeff Gonzales states $500 mln of repayments year-to-date have bolstered liquidity

* INVESTMENT ACTIVITY - CEO Bryan Donohoe highlights $360 mln of new loan commitments as part of portfolio repositioning

* RISK MANAGEMENT - CEO Bryan Donohoe mentions addressing risk rated 4 and 5 loans and reducing office loans to strengthen financial flexibility

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $5.63

Revenue mln

from

Real

Estate

Owned

Q3 EPS $0.08

Q3 Net Beat $4.65 $1.90

Income mln mln (5

Analysts

)

Q3 Beat $4.65 -$1.35

Pretax mln mln (3

Profit Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the specialized reits peer group is "buy."

* Wall Street's median 12-month price target for Ares Commercial Real Estate Corp ( ACRE ) is $4.50, about 0.2% below its November 6 closing price of $4.49

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Airbus beats Q3 expectations but cuts A220 production target
Airbus beats Q3 expectations but cuts A220 production target
Oct 29, 2025
PARIS (Reuters) -Europe's Airbus on Wednesday reported higher than expected third-quarter profits and revenues led by commercial jetliner deliveries and robust gains in helicopters and defence. It reaffirmed its main financial and delivery targets but cut the production goal for its smallest model and now aims to assemble 12 of the Canadian-designed A220s a month in 2026, down from a...
Starr Announces Acquisition of IQUW Group
Starr Announces Acquisition of IQUW Group
Oct 29, 2025
Starr set to become ninth-largest Lloyd’s agency NEW YORK & LONDON--(BUSINESS WIRE)-- Starr, a global investment and insurance organization, today announced that it has entered into a definitive agreement to acquire IQUW Group. The acquisition of IQUW Group will expand the classes of business that Starr underwrites and will position the combined company for growth across a broader range...
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
American Tower's Solid Q3 Results 'Overshadowed' by EchoStar Lawsuit, UBS says
Oct 29, 2025
12:34 PM EDT, 10/29/2025 (MT Newswires) -- American Tower's ( AMT ) solid Q3 results and slightly higher full-year guidance were overshadowed by a legal dispute with Echostar ( SATS ) over tower payments, but the market's reaction is overdone given the wireless infrastructure provider's minimal 2% revenue exposure to Echostar ( SATS ) and the stock's attractive valuation, UBS...
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China
Oct 29, 2025
12:32 PM EDT, 10/29/2025 (MT Newswires) -- Vor Biopharma ( VOR ) said Wednesday that its partner RemeGen presented 48-week data from a phase 3 study in China showing that telitacicept delivered consistent quality-of-life improvement in patients with generalized myasthenia gravis. All patients treated with telitacicept for 48 weeks achieved an at least two-point improvement in Myasthenia Gravis Activities of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved